comparemela.com

Page 3 - Alkermes Plc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top 10 valuation stocks with highest forward P/E (NYSEARCA:SPY)

Top 10 valuation stocks with highest forward P/E (NYSEARCA:SPY)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Innovations incLi auto incKe holdings incAlkermes plcSemler scientific incStoneco ltdSterling infrstructure incMacrogenics incSeeking alpha

Alkermes to Participate in Two Upcoming Investor Conferences

/PRNewswire/ Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor.

United statesPiper sandlerJamie constantineAnnual healthcare conferenceAnnual evercoreAlkermes plc

Investment Analysts New Coverage for November 18th (AIRG, AJX, ALIM, ALKS, APVO, CNET, CORR, DLNG, EVOK, GROW)

Investment Analysts’ new coverage for Saturday, November 18th: StockNews.com assumed coverage on shares of Airgain (NASDAQ:AIRG). They issued a hold rating on the stock. StockNews.com assumed coverage on shares of Great Ajax (NYSE:AJX). StockNews.com issued a sell rating on the stock. StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM). The firm issued a hold […]

Hersha hospitality trustInovio pharmaceuticalsPark city groupManitex internationalCorenergy infrastructure trustNews ratings for airgain inc dailyAlimera sciencesAirgain incInvestment analystGreat ajaxAptevo therapeuticsAction technologiesEvoke pharmaImpac mortgageSuperior drilling productsSangamo therapeutics

Alkermes spinout Mural Oncology launches with lead IL-2 drug

A year after Alkermes plc announced it would divide its oncology and neuroscience efforts into two separate businesses, the Dublin-based company spun out Mural Oncology plc with $275 million in funding and the lead solid tumor candidate nemvaleukin alfa. Shares of Mural (NASDAQ:MURA) will begin trading Nov. 16. “We’re very excited,” Mural’s CEO Caroline Loew told BioWorld. “We’ve got two major clinical datapoints in the next 18 months.”

Caroline loewMural oncologyAlkermes plcMural oncology plcOil 2Nemvaleukin alfaOvarian cancerInterleukin 2Platinum resistant ovarian cancerMucosal melanoma

Alkermes to Participate in the Jefferies London Healthcare Conference

/PRNewswire/ Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference.

United statesJamie constantineJefferies london healthcare conferenceAlkermes plc

vimarsana © 2020. All Rights Reserved.